With a large screen and microSD slot, this ClearClick converter can digitize your old analog footage with needing a computer ...

The Arizona Diamondbacks did well to bring back Zac Gallen, making sure their starting rotation is bolstered. However, they still need to address the depth in their bullpen. Fansided’s Christopher ...

State-appointed Superintendent Mike Miles said Houston ISD will convert Gregg and Clemente Martinez elementary schools into "Future 2 Schools" in 2026-27, launching new programs aimed at skills ...

Hudco's chairman and managing director Sanjay Kulshrestha. India’s state-run non-bank lender for housing and urban projects plans to raise $2 billion from multilateral agencies and through ...

Breaking space news, the latest updates on rocket launches, skywatching events and more! You are now subscribed Your newsletter sign-up was successful Want to add more newsletters? Delivered daily ...

ETFs offer a convenient way for investors to gain broad, diversified exposure to stocks. It's hard to beat Vanguard's S&P 500 ETF, which has delivered excellent results over time. Vanguard's ...

Zach Charbonnet, shown celebrating an earlier touchdown, helped the Seahawks convert a wild 2-point conversion. Soobum Im / Getty Images For as action-packed as the Seattle Seahawks’ rapid comeback ...

Things are getting nuts in Seattle. After the Rams took a 30–14, two-score lead over the Seahawks on Thursday night with less than a quarter to go, Seattle has since come back to tie the game, 30–30, ...

This Seattle Seahawks season keeps getting more and more strange. Remember the George Holani kickoff recovery touchdown earlier in the season? That was possibly the weirdest way an NFL team can score ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

Q32 Bio on Monday sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics Inc. (NASDAQ: AKBA). ADX-097, the lead product candidate from Q32 Bio’s tissue-targeted complement inhibitor ...

-- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the ...